Metabolic shares suspended
10 June, 2005 by Ruth BeranMelbourne based Metabolic Pharmaceuticals (ASX:MBP) has suspended its shares from the ASX's official quotation in the lead-up to an announcement.
In brief: C3, GTG, Avantogen, Alchemia
09 June, 2005 by Ruth BeranClinical Cell Culture (C3, ASX:CCE) will launch CellSpray XP commercially in Europe next week at a meeting in Germany. Following the launch CellSpray XP will be available for sale in those European countries where it has regulatory approval - Austria, Denmark, Germany, Italy, The Netherlands, Switzerland and the UK.
Opara steps down as Polartechnics chair
09 June, 2005 by Ruth BeranRichard Opara has stepped down from his role as interim chairman of device company Polartechnics (ASX:PLT), and is replaced by corporate financial advisor Robert Hunter.
Biota boosted by antiviral find
09 June, 2005 by Susan WilliamsonBiota Holdings (ASX:BTA) has developed a new class of orally-effective antivirals against respiratory syncytial virus (RSV) infection that the company hopes will go to Phase I trials by 2006.
Peptech to advance anti-TNF drug after preclinical study
08 June, 2005 by Staff WritersPeptech (ASX:PTD) has claimed "significant" results in a preclinical study of its human domain antibody (dAb) therapeutic -- potency levels three times higher than the current market-leading anti-TNF drug against rheumatoid arthritis.
BioProspect claims success in termite trial
08 June, 2005 by Graeme O'NeillThe tract of bushland near Narrandera, in southern NSW, where Brisbane natural pesticide developer BioProspect (ASX:BPO) is field-trialling its promising termiticide AP778 teems with voracious termites.
Pharma-sponsored trial result reporting biased: report
07 June, 2005 by Graeme O'NeillA survey of Australian medical research specialists has found that bias and manipulation in reporting of clinical trial results are rife when the trials are sponsored by pharmaceutical companies.
Metabolic unveils obesity drug trial details
06 June, 2005 by Ruth BeranMelbourne-based Metabolic Pharmaceuticals (ASX:MBP) has clarified details of a previously announced Phase IIb trial of its anti-obesity drug AOD9604, with recruitment expected to commence in September or October this year.
Biotech stocks steadied in May: Intersuisse
06 June, 2005 by Ruth BeranWhile biotechnology stocks have suffered in the first five months of 2005 -- with the Intersuisse biotechnology index showing a 23 per cent fall since December 31 -- the index stabilised in May with a 0.28 per cent gain.
FDA advances Neuren's Phase III to next year
06 June, 2005 by Ruth BeranNZ-based Neuren (ASX:NEU) has received confirmation from the US Food and Drug Administration (FDA) that the company can bypass a previously planned Phase IIb study for its lead drug Glypromate and advance directly to a major Phase III efficacy study.
Phenomix closes US$40 million series B financing
03 June, 2005 by Ruth BeranPhenomix, based in Canberra and San Diego, has closed a US$40 million private placement of its series B preferred stock, with new US investors JPMorgan Partners and Delphi Ventures co-leading the financing.
Progen explains share price dip
03 June, 2005 by Ruth BeranBrisbane cancer-drug developer Progen (ASX:PGL) has responded to an ASX 'please explain' in response to its flagging share price, citing the expiry of listed options on May 31 and speculation of a larger than expected shortfall as possible.
Mesoblast tech may be used to treat injured AFL star
03 June, 2005 by Ruth BeranThe orthopaedic surgeon of an injured AFL football player is considering using Melbourne-based stem cell specialist Mesoblast's (ASX:MSB) technology to accelerate bone regeneration in the footballer's fractured leg, the company has claimed.
FDA approves GroPep-based biopharma product
02 June, 2005 by Ruth BeranA biopharmaceutical product that uses GroPep's (ASX:GRO) cell culture products in its manufacturing process has received US Food and Drug Administration (FDA) regulatory approval.
Domantis find expected to benefit Abbott
02 June, 2005 by Graeme O'NeillUK antibody therapeutics developer Domantis has pulled a double-headed rabbit out of the hat for its client, the big European pharma Abbott Laboratories.
